Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base.


Journal

Therapeutic advances in respiratory disease
ISSN: 1753-4666
Titre abrégé: Ther Adv Respir Dis
Pays: England
ID NLM: 101316317

Informations de publication

Date de publication:
Historique:
entrez: 18 5 2019
pubmed: 18 5 2019
medline: 16 11 2019
Statut: ppublish

Résumé

Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 µg is a twice-daily long-acting muscarinic receptor antagonist and long-acting β

Identifiants

pubmed: 31096854
doi: 10.1177/1753466619850725
pmc: PMC6535700
doi:

Substances chimiques

Adrenergic beta-2 Receptor Agonists 0
Bronchodilator Agents 0
Drug Combinations 0
Muscarinic Antagonists 0
Tropanes 0
aclidinium bromide UQW7UF9N91
Formoterol Fumarate W34SHF8J2K

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1753466619850725

Références

Int J Chron Obstruct Pulmon Dis. 2017 Mar 17;12:907-922
pubmed: 28360514
Respir Med. 2011 Dec;105(12):1861-71
pubmed: 21807487
Respir Med. 2011 Jun;105(6):930-8
pubmed: 21367593
Respir Med. 2016 Jul;116:41-8
pubmed: 27296819
Int J Chron Obstruct Pulmon Dis. 2017 Aug 24;12:2545-2558
pubmed: 28883722
Respir Med. 2009 Dec;103(12):1832-7
pubmed: 19651504
Drug Discov Today. 2014 Dec;19(12):1928-35
pubmed: 25182512
Eur Respir J. 2014 Jun;43(6):1590-8
pubmed: 24488571
Am J Respir Crit Care Med. 2014 Feb 1;189(3):250-5
pubmed: 24383418
Thorax. 2014 May;69(5):443-9
pubmed: 24595666
N Engl J Med. 2010 Sep 16;363(12):1128-38
pubmed: 20843247
NPJ Prim Care Respir Med. 2017 Dec;27(1):13
pubmed: 28235977
Respir Res. 2014 Oct 14;15:123
pubmed: 25756831
Eur Respir J. 2015 Oct;46(4):988-1000
pubmed: 26022965
Eur Respir J. 2017 Mar 6;49(3):
pubmed: 28182564
Lancet Respir Med. 2016 May;4(5):390-8
pubmed: 27066739
BMC Pulm Med. 2014 Nov 18;14:178
pubmed: 25404569
COPD. 2006 Dec;3(4):219-32
pubmed: 17361503
Lancet Respir Med. 2014 Mar;2(3):195-203
pubmed: 24621681
COPD. 2005 Mar;2(1):111-24
pubmed: 17136971
Eur Respir J. 2016 Oct;48(4):1030-1039
pubmed: 27492833
Expert Opin Drug Discov. 2018 Jun;13(6):563-577
pubmed: 29616842
Am J Med. 2006 Oct;119(10 Suppl 1):32-7
pubmed: 16996897
Am J Respir Crit Care Med. 2017 May 1;195(9):1189-1197
pubmed: 28278391
N Engl J Med. 2018 May 03;378(18):1671-1680
pubmed: 29668352
COPD. 2005 Mar;2(1):99-103
pubmed: 17136969
Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55
pubmed: 17507545
Expert Opin Drug Deliv. 2013 Aug;10(8):1023-31
pubmed: 23745954
Pulm Pharmacol Ther. 2010 Aug;23(4):257-67
pubmed: 20381630
Thorax. 2002 Oct;57(10):847-52
pubmed: 12324669
Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7
pubmed: 1759018
J Med Chem. 2009 Aug 27;52(16):5076-92
pubmed: 19653626
Chest. 2002 May;121(5):1434-40
pubmed: 12006425
Ann Intern Med. 2015 Sep 15;163(6):461-4
pubmed: 26259067
Respir Res. 2014 Oct 21;15:122
pubmed: 25331383
COPD. 2005 Mar;2(1):75-9
pubmed: 17136966
Respir Med. 2015 Jul;109(7):785-802
pubmed: 25892293
Am J Respir Med. 2002;1(4):285-300
pubmed: 14720051
J Med Chem. 2015 May 28;58(10):4131-64
pubmed: 25587755
BMC Health Serv Res. 2016 Jul 12;16:251
pubmed: 27406133
BMC Pulm Med. 2014 Dec 23;14:209
pubmed: 25539654
Clin Ther. 2010 Sep;32(10):1798-812
pubmed: 21194604
Int J Clin Pract. 2012 Mar;66(3):309-17
pubmed: 22340451
Drug Discov Today. 2016 Nov;21(11):1820-1827
pubmed: 27452453
Int J Chron Obstruct Pulmon Dis. 2016 Aug 29;11:2041-53
pubmed: 27621610
J Gen Intern Med. 2008 Nov;23(11):1829-34
pubmed: 18795373
Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22
pubmed: 9603117
Clinicoecon Outcomes Res. 2016 Sep 12;8:445-56
pubmed: 27672337
Respir Med. 2018 May;138:21-31
pubmed: 29724389
Value Health. 2010 Dec;13(8):965-75
pubmed: 20659270
Prim Care Respir J. 2013 Mar;22(1):101-11
pubmed: 23429861
Multidiscip Respir Med. 2016 Feb 10;11:7
pubmed: 26865979
Chronic Obstr Pulm Dis. 2015 Dec 22;3(1):435-445
pubmed: 28848864
NPJ Prim Care Respir Med. 2015 Apr 30;25:15018
pubmed: 25927321
Respir Med. 2017 Apr;125:39-48
pubmed: 28340861
J Pharmacol Exp Ther. 2009 Nov;331(2):740-51
pubmed: 19710368
Respir Res. 2017 May 30;18(1):106
pubmed: 28558833
Curr Med Chem. 2013;20(12):1464-76
pubmed: 22963553
Am J Respir Crit Care Med. 2017 Nov 1;196(9):1098-1100
pubmed: 29090962
Eur Respir J. 2009 Sep;34(3):648-54
pubmed: 19720809
Respir Res. 2015 Aug 02;16:92
pubmed: 26233481
Eur J Pharm Sci. 2010 Mar 18;39(5):283-90
pubmed: 20093184

Auteurs

Anthony D D'Urzo (AD)

Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON 12354, Canada.

Dave Singh (D)

Medicines Evaluation Unit, Manchester University NHS Foundations Trust, Manchester, UK.

James F Donohue (JF)

Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina Pulmonary Critical Medicine, Chapel Hill, NC, USA.

Kenneth R Chapman (KR)

Asthma and Airway Center, Toronto Western Hospital, Toronto, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH